The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: A case-crossover study

Thorax

Volumn 63, Issue 8, 2008, Pages 677-682

  Hauser, T ^a,b   Mahr, A ^a   Metzler, C ^c   Coste, J ^a   Sommerstein, R ^b   Gross, W L ^c   Guillevin, L ^a   Hellmich, B ^c  

^a Université Paris 5 ^*  (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; MONTELUKAST; PREDNISOLONE; PREDNISONE; SALMETEROL;

ADULT; ARTICLE; ASTHMA; CASE CROSS OVER STUDY; CHURG STRAUSS SYNDROME; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FRANCE; GERMANY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METHODOLOGY; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT;

EID: 49149105615     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.087825     Document Type: Article

References (42)

1. Conron M, Beynon HL. Churg-Strauss syndrome. Thorax 2000;55:870-7.
2. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003;361:587-94.
3. Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. Thorax 1999;54:558-60.
4. Josefson D. Asthma drug linked with Churg-Strauss syndrome. BMJ 1997;315:330.
5. Kinoshita M, Shiraishi T, Koga T, et al. Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol 1999;103:534-5.
6. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
7. Pagnoux C, Guilpain P, Hauser T, et al. Churg-Strauss syndrome and leukotriene-modifying agents. Clinical Pulmonary Medicine 2004;11:349-54.
8. Weller PF, Plaut M, Taggart V, et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001;108:175-83.
9. Stirling RG, Chung KF. Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun. Thorax 1999;54:865-6.
10. Honsinger RW. Zafirlukast and Churg-Strauss syndrome (with discussion). JAMA 1998;279:1949-50.
11. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999;353:725-6.
12. Katz RS, Papernik M. Zafirlukast and Churg-Strauss syndrome (with discussion). JAMA 1998;279:1949-50.
13. Knoell DL, Lucas J, Allen JN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998;114:332-4.
14. Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax 2000;55:805-6.
15. Villena V, Hidalgo R, Sotelo MT, et al. Montelukast and Churg-Strauss syndrome. Eur Respir J 2000;15:626.
16. Ducharme F, Schwartz Z, Hicks G, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004:CD003133.
17. Barnes NC. Clinical tolerability of zafirlukast, a new oral antileukotriene drug. Eur Respir Rev 1998;8:194-8.
18. Cooper SM, Libman BS, Lazarovich M. Churg-Strauss syndrome in a group of patients receiving fluticasone for asthma. J Rheumatol 2002;29:2651-2.
19. D'Cruz DP, Barnes NC, Lockwood CM. Difficult asthma or Churg-Strauss syndrome? BMJ 1999;318:475-6.
20. Le Gall C, Pham S, Vignes S, et al. Inhaled corticosteroids and Churg-Strauss syndrome: a report of five cases. Eur Respir J 2000;15:978-81.
21. Wechsler ME, Finn D, Gunawardena D, et al. Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 2000;117:708-13.
22. Harrold LR, Patterson MK, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome. Pharmacoepidemiol Drug Saf 2007;16:620-6.
23. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and 6 or 12 cyclophosphamide pulses in 48 patients. Arthritis Rheum 2007;57:686-93.
24. Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a prospective study on 72 patients. Arthritis Rheum 2008;58:586-94.
25. Anon. Fachinformation Singulair. MSD/Dieckmann Arzneimittel GmbH. Stand Mai 2006.
26. Anon. Avis d'octroi d'autorisations de mise sur le marché de spécialités pharmaceutiques. Bulletin Officiel No 98-51. SP 2 263 3215.
27. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-100.
28. Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984;63:65-81.
29. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
30. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-53.
31. Hellmich B, Ehlers S, Csernok E, et al. Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2003;21(Suppl 32):S69-77.
32. Mittleman MA, Maclure M, Robins JM. Control sampling strategies for case-crossover studies: an assessment of relative efficiency. Am J Epidemiol 1995;142:91-8.
33. Etminan M, Gill S, Fitzgerald M, et al. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making. J Clin Pharmacol 2006;46:6-9.
34. Viboud C, Boelle PY, Kelly J, et al. Comparison of the statistical efficiency of case-crossover and case-control designs: application to severe cutaneous adverse reactions. J Clin Epidemiol 2001;54:1218-27.
35. Wang PS, Schneeweiss S, Glynn RJ, et al. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol 2004;14:296-303.
36. Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology 1996;7:231-9.
37. Cooper BJ, Bacal E, Patterson R. Allergic angiitis and granulomatosis. Prolonged remission induced by combined prednisone - azathioprine therapy. Arch Intern Med 1978;138:367-71.
38. Haas C, Géneau C, Odinot JM, et al. Allergic angiitis with granulomatosis: Churg-Strauss syndrome. Retrospective study of 16 cases (French). Ann Méd Interne (Paris) 1991;142:335-42.
39. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005;28:851-70.
40. Bili A, Condemi JJ, Bottone SM, et al. Seven cases of complete and incomplete forms of Churg-Strauss syndrome not related to leukotriene receptor antagonists. J Allergy Clin Immunol 1999;104:1060-5.
41. Lobel H, Machtey I, Eldror MY. Pulmonary infiltrates with eosinophilia in an asthmatic patient treated with disodium cromoglycate. Lancet 1972;2:1032.
42. Wong CS, Cooper S, Britton JR, et al. Steroid sparing effect of nedocromil sodium in asthmatic patients on high doses of inhaled steroids. Clin Exp Allergy 1993;23:370-6.